Unusual Adverse Effects of Immune Checkpoint Inhibitors: Autonomic Neuropathy, Palmoplantar Keratoderma, Reiter Syndrome & Myasthenia Gravis: A Case Series and Review of the Literature
-
Published:2020-11-23
Issue:11
Volume:5
Page:554-560
-
ISSN:2455-8737
-
Container-title:International Journal of Innovative Research in Medical Science
-
language:
-
Short-container-title:ijirms
Author:
Shalata Walid,Yakobson Alexander,Massalha Ismaell,Y. Cohen Aharon,Goldstein Iris M.,Gibbs Rachel,Omar Abu Saleh,Asla Mohnnad,Dudnik Yulia,Abu-Juma'a Ali,Peled Nir,Rouvinov Keren
Abstract
The immune checkpoint inhibitors (ICIs) have transformed the standards of care in cancer treatment and has dramatically improved patient prognoses. As a result of the introduction of these novel treatments several types of adverse events related to ICIs (immune related adverse events ((irAEs)) have been observed and reported. In this case series we describe the clinical course of four patients, with unusual ICI induced toxicities. The first patient was a 59 year-old female who received chemo-immunotherapy (pembrolizumab) for stage 4- lung adenocarcinoma, and developed autonomic neuropathy (AN). The second and third patients were both 63 year-old males who also received chemo-immunotherapy (pembrolizumab) for stage 4-A lung adenocarcinoma. One of those patients developed palmoplantar keratoderma and one developed conjunctivitis, urethritis and arthritis (Reiter syndrome). The fourth patient was an 80 year-old male who received chemo-immunotherapy (pembrolizumab) for stage 3-A squamous cell carcinoma of the lung and developed myasthenia gravis.
Publisher
International Scientific Invention Journals
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献